- Total of 200 million doses ordered by the U.S government to date; U.S. government retains option to purchase up to an additional 300 million doses
- Approximately 20 million doses will be delivered by the end of December 2020
- Moderna intends to submit a Biologics License Application for full U.S. licensure in 2021
Category Archives: AZBio News
Payroll R&D Credit Five Years Later: Forging a New Path
By John Guy, Manager, Emerging Companies Policy at Biotechnology Innovation Organization
December 18, 2020: Five years ago today, the Protecting Americans from Tax Hikes (PATH) Act was signed into law. This important piece of legislation included several provisions helpful to start ups like small biotechs, including permanently extending both the R&D Credit and the Small Business Stock Gains Exclusion (Tax Code Section 1202), providing both investors and the companies they invest in security without worry of losing access to the critical incentive in the future.
HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz., Dec. 18, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has signed up the first collaborator in its recently announced Early Access Program for its prototype whole transcriptome panel.Continue reading
Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma
Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma. The Ivy Brain Tumor Center’s Phase 0 clinical trials program is the largest of its kind in the world and enables personalized care in a fraction of the time and cost associated with traditional drug development.Continue reading
iMetabolic Biopharma Corporation Announces Expansion of its Strategic OmniAb Antibody Discovery Partnership with Ligand Pharmaceuticals Accelerating iMetabolic’s iPlatform™ Technology and Pipeline Development
TEMPE, Ariz.–(BUSINESS WIRE)–iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligand’s OmniAb platform. Continue reading
C-Path and Diamyd Medical Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes
TUCSON, Ariz., and STOCKHOLM, Sweden. December 16, 2020 — The Critical Path Institute (C-Path) and Diamyd Medical (DMYD B; Nasdaq First North Growth Market) are proud to announce their collaboration to significantly improve the scientific community’s insight into type 1 diabetes (T1D) through Diamyd Medical’s contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Markers Initiative (TOMI-T1D) integrated database. The Phase III trial evaluated the use of the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. The Data Contribution Agreement (DCA) between Diamyd Medical and C-Path will allow for this unique set of fully anonymized clinical trial data to be integrated into an ever-growing list of committed trial data sets within the TOMI-T1D project.Continue reading
AZBio Career Center Launches Expanded Career Planning Portal
The Career Planning Portal by YM Careers®, a component of the AZBio Career Center that allows AZBio Members to create an account and access tools for researching, planning and developing their careers for years to come!Continue reading
Rockefeller Foundation’s third National Covid-19 Testing Action Plan calls on the U.S. government to massively scale up Covid-19 testing
Rockefeller Foundation’s third National Covid-19 Testing Action Plan calls on the U.S. government to massively scale up Covid-19 testing an lays out a new plan for the largest domestic testing scale up to date and proposes 14 executive actions for the current and incoming administrations to take in order to rapidly alter the trajectory of the pandemic in the United States. Testing all U.S. public K-12 public schools would cost $42.5 billion, or $8.5 billion per month for the remainder of the school year from February to June 2021.Continue reading
Opportunity Alert – Applications for TGen’s Summer Program are Now Open
Helios Scholars at TGen offers students full-time, paid internship opportunities that include research experience and professional development in the field of biomedical research.Continue reading